SELLAS Life Sciences Group Inc.

5 days ago · prnewswire.com

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).

20 days ago · globenewswire.com

-  Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer –  -  Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that three abstracts evaluating SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, in preclinical models of pancreatic ductal adenocarcinoma (PDAC) have been accepted for poster presentation at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.

26 days ago · benzinga.com

SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the stock has surged by around 300%.

1 month ago · globenewswire.com

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -  - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “The second quarter was an important period of execution for SELLAS as we continued to advance both of our lead clinical programs, GPS and SLS009,” said Angelos Stergiou, MD, ScD h.c.

2 months ago · seekingalpha.com

SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.

3 months ago · benzinga.com

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Wednesday as investors take profits following the stock's strong longer-term uptrend, with broader risk appetite also softer across equities.

3 months ago · benzinga.com

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Tuesday as traders digest the recent breakout run and early profit-taking shows up even with momentum still elevated from the company's latest corporate update.

3 months ago · invezz.com

Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.

3 months ago · benzinga.com

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are pushing higher Friday morning, adding to Thursday's strong rally.

3 months ago · benzinga.com

Shares of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are rallying sharply Thursday, hitting a fresh 52-week high of $11.06, up over 16% in midday trading. The clinical-stage biopharmaceutical company is experiencing a massive surge in volume following a regulatory filing.